Diphenoxylate

Drug class: Antineoplastic Agents

Usage of Diphenoxylate

Diarrhea

Adjunctive therapy in the management of diarrhea.

Symptomatic treatment of mild or uncomplicated travelers’ diarrhea, including that occurring in adult travelers with HIV infection. Should not be used in travelers with severe diarrhea or with high fever or blood in the stools; these travelers may benefit from short-term treatment with an anti-infective (e.g., a fluoroquinolone).

Ineffective for prevention of travelers’ diarrhea; may increase incidence of travelers’ diarrhea.

Relate drugs

How to use Diphenoxylate

Administration

Oral Administration

In children 2–12 years of age, administer as oral solution using only the calibrated measuring device provided by the manufacturer.

Do not administer in children <2 years of age because of the narrow range between therapeutic and toxic doses in this age group.

Discontinue if symptoms of travelers’ diarrhea persist >48 hours or worsen.

Dosage

Available as diphenoxylate hydrochloride; dosage expressed in terms of the salt. Commercially available only in combination with atropine sulfate (in subtherapeutic quantity to discourage deliberate overdosage).

Pediatric Patients

Diarrhea Oral

Children 2–12 years of age: Initially, 0.3–0.4 mg/kg daily, given in 4 divided doses.

Approximate Initial Dosage for Children 2–12 Years of AgeBC

Age

Approximate Weight

Dosage in mg (mL of 2.5-mg/5-mL oral solution)

2 years

11–14 kg

0.75–1.5 mg (1.5–3 mL) 4 times daily

3 years

12–16 kg

1–1.5 mg (2–3 mL) 4 times daily

4 years

14–20 kg

1–2 mg (2–4 mL) 4 times daily

5 years

16–23 kg

1.25–2.25 mg (2.5–4.5 mL) 4 times daily

6–8 years

17–32 kg

1.25–2.5 mg (2.5–5 mL) 4 times daily

9–12 years

23–55 kg

1.75–2.5 mg (3.5–5 mL) 4 times daily

Children 13–16 years of age: Initially, 5 mg 3 times daily.

Pediatric dosage schedules are approximations of an average dosage recommendation; adjust dosage downward according to overall nutritional status and degree of dehydration.

Continue dosage at initial levels until symptoms are controlled and then reduce for maintenance as required; not likely to be effective if no response occurs within 48 hours.

Maintenance dosages may be as low as one-fourth the initial daily dosage.

Adults

Diarrhea Oral

Initially, 5 mg 4 times daily.

Continue dosage at initial level until symptoms are controlled and then reduce for maintenance as required; not likely to be effective for treatment of acute diarrhea if no response occurs within 48 hours.

Maintenance dosage may be as low as one-fourth (e.g., 5 mg daily) the initial daily dosage.

If clinical improvement of chronic diarrhea after treatment with a maximum daily dosage of 20 mg is not observed within 10 days, symptoms are unlikely to be controlled by further administration.

Prescribing Limits

Do not exceed recommended dosage.

Pediatric Patients

Diarrhea Oral

Children 2–12 years of age: 0.4 mg/kg daily in divided doses.

Children 13–16 years of age: 5 mg 3 times daily.

Adults

Diarrhea Oral

20 mg daily in divided doses.

Warnings

Contraindications

  • Known hypersensitivity to diphenoxylate or atropine.
  • Obstructive jaundice.
  • Diarrhea associated with pseudomembranous enterocolitis or enterotoxin-producing bacteria.

    • Warnings/Precautions

    Warnings

    Do not use in patients with diarrhea caused by poisoning until the toxic material is eliminated from the GI tract by gastric lavage or cathartics.

    Do not use in patients with high fever or blood in stools.

    Acute Toxicity

    Overdosage may result in severe respiratory depression and coma, possibly leading to permanent brain damage or death. Adhere strictly to dosage recommendations.

    Respiratory depression is possible up to 30 hours after ingestion and may recur despite initial response to an opiate antagonist.

    MAO Inhibitors

    Because diphenoxylate is structurally similar to meperidine, consider the possibility of hypertensive crisis if diphenoxylate and MAO inhibitors are used concomitantly.

    Fluid and Electrolyte Replacement Therapy

    Appropriate fluid and electrolyte replacement therapy is recommended, when indicated. If severe dehydration or electrolyte imbalance is present, withhold diphenoxylate until appropriate corrective therapy has been initiated.

    Drug-induced inhibition of peristalsis may result in fluid retention in the intestine, which may further aggravate dehydration and electrolyte imbalance; may mask fluid and electrolyte depletion in treatment of acute enteritis, especially in young children.

    Infectious Diarrhea and Pseudomembranous Enterocolitis

    Antiperistaltic agents may prolong and/or worsen diarrhea resulting from some infections (e.g., those caused by Shigella, Salmonella, toxigenic Escherichia coli) and from pseudomembranous enterocolitis associated with broad spectrum antibiotics; do not use in these conditions.

    Ulcerative Colitis

    Toxic megacolon reported with agents that inhibit intestinal motility or prolong intestinal transit time in some patients with acute ulcerative colitis. Carefully observe patients with acute ulcerative colitis; discontinue promptly if abdominal distention occurs or other adverse symptoms develop.

    Hepatic Effects

    Hepatic coma reported in patients with cirrhosis. Use with extreme caution in patients with cirrhosis, advanced hepatorenal disease, or abnormal liver function tests results. Contraindicated in patients with jaundice.

    General Precautions

    Prescribing and Dispensing Errors

    Ensure accuracy of prescription; similarity in spelling of Lomotil (fixed combination of diphenoxylate hydrochloride and atropine sulfate) and Lamictal (lamotrigine, an anticonvulsant agent) may result in errors.

    Fixed Combination

    Commercially available only in combination with atropine sulfate. Consider the cautions, precautions, and contraindications associated with atropine.

    Abuse Potential

    Evidence of physical dependence not reported with recommended dosages. Possibility of dependence when given in high dosage.

    Specific Populations

    Pregnancy

    Category C.

    Lactation

    Active metabolite (diphenoxylic acid) may be distributed into milk; atropine is distributed into milk. Drug effects may occur in breast-fed infants. Caution advised if used in nursing women.

    Pediatric Use

    Not recommended for children <2 years of age. Use particular caution in young children due to greater variability of responses to the drug. Consider nutritional status and degree of dehydration. (See Fluid and Electrolyte Replacement Therapy under Cautions.)

    Not recommended for treatment of travelers’ diarrhea in infants, children, or adolescents with HIV infection.

    Consider precautions related to use of atropine in children; use with caution since signs of atropinism may occur even at recommended dosages, particularly in patients with Down’s syndrome.

    Hepatic Impairment

    Use with extreme caution in patients with cirrhosis, advanced hepatorenal disease, or abnormal liver function test results, since hepatic coma may be precipitated. Contraindicated in patients with jaundice.

    Common Adverse Effects

    Nausea, vomiting, abdominal discomfort or distention, sedation, dizziness, pruritus, anorexia, restlessness or insomnia, confusion, headache.

    What other drugs will affect Diphenoxylate

    Inhibits hepatic microsomal CYP isoenzymes at a dosage of 2 mg/kg daily.

    Drugs Metabolized by Hepatic Microsomal Enzymes

    Possible pharmacokinetic interaction (increased plasma concentrations of enzyme substrate).

    Specific Drugs

    Drug

    Interaction

    Comments

    CNS depressants (e.g., alcohol, barbiturates, tranquilizers)

    Increased CNS depression

    Monitor closely if used concomitantly

    MAO inhibitors

    Concomitant use theoretically may precipitate hypertensive crisis

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords

    AI Assitant